PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-08-26
DOI
10.1038/s41598-017-10925-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung
- (2018) Ayako Hirai et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases
- (2017) Hironori Uruga et al. Journal of Thoracic Oncology
- The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma
- (2017) Kazuki Takada et al. LUNG CANCER
- Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer
- (2017) Satoshi Igawa et al. ONCOLOGY
- PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer
- (2017) Cuiling Zhou et al. Oncotarget
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer treatment and survivorship statistics, 2016
- (2016) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations
- (2016) Mei Ji et al. CANCER BIOLOGY & THERAPY
- High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma
- (2016) Yih-Leong Chang et al. EUROPEAN JOURNAL OF CANCER
- Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
- (2016) Takaaki Tokito et al. EUROPEAN JOURNAL OF CANCER
- Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma
- (2016) Ching-Yao Yang et al. EUROPEAN JOURNAL OF CANCER
- Relationship of tumor PD-L1 expression withEGFRwild-type status and poor prognosis in lung adenocarcinoma
- (2016) Kentaro Inamura et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
- (2016) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma
- (2016) Kazuki Takada et al. Journal of Thoracic Oncology
- Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment
- (2016) Tiffany G. Huynh et al. Journal of Thoracic Oncology
- Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases
- (2016) Jong-Mu Sun et al. Journal of Thoracic Oncology
- Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma
- (2016) Zhengbo Song et al. Journal of Translational Medicine
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status
- (2016) Yoon Jin Cha et al. LUNG CANCER
- Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)
- (2016) Masaki Shimoji et al. LUNG CANCER
- PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
- (2016) Matthew W Rosenbaum et al. MODERN PATHOLOGY
- PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome
- (2016) Marius Ilie et al. MODERN PATHOLOGY
- High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases
- (2016) Shohei Mori et al. PATHOLOGY INTERNATIONAL
- PD-L1 Expression and Survival among Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy
- (2016) Steffen Filskov Sorensen et al. Translational Oncology
- Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions
- (2016) Feifei Teng et al. Oncotarget
- PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
- (2016) Francesco Passiglia et al. Oncotarget
- Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer
- (2016) Yusuke Inoue et al. Oncotarget
- Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants
- (2016) Subrata Chowdhury et al. Oncotarget
- Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC)
- (2016) Qinxiang Guo et al. Thoracic Cancer
- PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC
- (2016) Malaka Ameratunga et al. PLoS One
- Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors
- (2015) Z. Cierna et al. ANNALS OF ONCOLOGY
- Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer
- (2015) Raffaele Califano et al. CANCER TREATMENT REVIEWS
- Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
- (2015) K. Ota et al. CLINICAL CANCER RESEARCH
- Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma
- (2015) Cheng Lin et al. Clinical Lung Cancer
- The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis
- (2015) A. Wang et al. EJSO
- Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
- (2015) Hidenobu Ishii et al. Journal of Thoracic Oncology
- Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers
- (2015) Moon-Young Kim et al. LUNG CANCER
- PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
- (2015) Wendy A. Cooper et al. LUNG CANCER
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis
- (2015) Roberto Iacovelli et al. Targeted Oncology
- Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis
- (2015) Anyuan Zhong et al. OncoTargets and Therapy
- High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
- (2015) Tao Qin et al. Oncotarget
- PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival
- (2015) Wenfeng Fang et al. Oncotarget
- B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer
- (2015) Yixiang Mao et al. Oncotarget
- The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
- (2015) Yanna Tang et al. Oncotarget
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
- (2014) K. Azuma et al. ANNALS OF ONCOLOGY
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- (2014) A D'Incecco et al. BRITISH JOURNAL OF CANCER
- Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
- (2014) Ching-Yao Yang et al. EUROPEAN JOURNAL OF CANCER
- Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
- (2014) Yang Zhang et al. OncoTargets and Therapy
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
- (2010) Andreas Stang EUROPEAN JOURNAL OF EPIDEMIOLOGY
- High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
- (2010) Chuan-Yong Mu et al. MEDICAL ONCOLOGY
- Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
- (2010) David Moher et al. International Journal of Surgery
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More